Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) EBIT Margin (2016 - 2020)

Historic EBIT Margin for KalVista Pharmaceuticals (KALV) over the last 7 years, with Q2 2020 value amounting to 234.23%.

  • KalVista Pharmaceuticals' EBIT Margin rose 1505900.0% to 234.23% in Q2 2020 from the same period last year, while for Apr 2020 it was 319.42%, marking a year-over-year decrease of 1344900.0%. This contributed to the annual value of 3249.7% for FY2025, which is 35305900.0% up from last year.
  • Latest data reveals that KalVista Pharmaceuticals reported EBIT Margin of 234.23% as of Q2 2020, which was up 1505900.0% from 806.85% recorded in Q1 2020.
  • Over the past 5 years, KalVista Pharmaceuticals' EBIT Margin peaked at 61.34% during Q2 2018, and registered a low of 93257.14% during Q1 2016.
  • In the last 5 years, KalVista Pharmaceuticals' EBIT Margin had a median value of 384.83% in 2019 and averaged 6612.27%.
  • In the last 5 years, KalVista Pharmaceuticals' EBIT Margin tumbled by -232428600bps in 2016 and then soared by 54916900bps in 2018.
  • Quarter analysis of 5 years shows KalVista Pharmaceuticals' EBIT Margin stood at 2043.15% in 2016, then surged by 74bps to 526.8% in 2017, then surged by 83bps to 87.5% in 2018, then crashed by -171bps to 236.96% in 2019, then grew by 1bps to 234.23% in 2020.
  • Its EBIT Margin was 234.23% in Q2 2020, compared to 806.85% in Q1 2020 and 236.96% in Q4 2019.